Adherence to the bowel cleansing regimen for pan-enteric capsule endoscopy in patients with suspected Crohn’s disease and factors affecting the image quality

Author(s):  
Jacob Broder Brodersen ◽  
Karina Winther Andersen ◽  
Michael Dam Jensen
2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S249-S250
Author(s):  
B Jacob Broder ◽  
A Karina Winther ◽  
M D Jensen

Abstract Background Pan-enteric capsule endoscopy (CE) is an attractive diagnostic approach in patients examined for Crohn’s disease (CD). The current bowel cleansing regimen was developed for patients with suspected gastrointestinal neoplasia (polyps). Since the majority of patients with CD have diarrhoea, a reduced volume of bowel preparation may be sufficient for cleansing the colon. The aim of this study was to examine the adherence to the recommended bowel cleansing regimen in patients with suspected CD examined with pan-enteric CE and determine clinical factors affecting the image quality. Methods Patients with clinically suspected CD were prospectively enrolled in a trial examining non-invasive modalities for diagnosing CD (http://ClinicalTrials.gov Identifier NCT03134586). All patients had a standardized work-up including medical history, physical examination, blood and stool samples and pan-enteric CE. CE was performed with the PillCam™ Crohn’s capsule (Medtronic, Dublin, Ireland) after overnight fasting and bowel preparation with 2 + 2 litres of Polyethylene glycol (Moviprep®, PEG + ascorbic acid) and Sodium Phosphate booster as previously described by ESGE. Readers were blinded to the results of other examinations. The image quality was graded on a 4-point scale (poor, fair, good, excellent). A good or excellent image quality defined a diagnostic procedure. Results The volume of ingested PEG was recorded in 59 patients (Table 1). The mean volume was 2.5 L (CI 2.3–2.8). 10 patients (17%) were able to drink all 4 L of PEG, and 44 patients (75%) ingested > 2 L. The image quality was poor, fair, good or excellent in 0%, 29.3%, 29.3% and 41.4%, respectively. The mean volume of PEG was 1.9 L (CI 1.4–2.4), 2.2 L (CI 1.8–2.7) and 3.2 L (CI 2.8–3.5) in patients with a fair, good or excellent image quality (P < 0,001, Figure 1). In a regression analysis including multiple clinical variables, only the volume of ingested PEG was associated with the obtained image quality (Spearman’s rho = 0.52; P < 0.001). Stool consistency, number of bowel movements, diagnosis of inflammatory bowel disease (IBD) or the degree of inflammation did not affect the image quality. The diagnostic yield was equal in patients with a diagnostic or non-diagnostic image quality (44% and 44%, respectively). The capsule was excreted in 53 patients (90%), and the analysis was not able to determine factors affecting the completion rate. Conclusion In patients examined with pan-enteric CE for suspected CD, the ingested volume of PEG is the major factor affecting the image quality. However, only few patients are able to ingest the recommended volume. Future research should determine the optimal bowel cleansing regimen for patients examined for IBD.


2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S373-S373
Author(s):  
A Volkers ◽  
P Bosuyt ◽  
J de Jong ◽  
G D’Haens ◽  
M Löwenberg

Abstract Background Pan-enteric capsule endoscopy (pan-CE) visualizes the entire gastrointestinal tract and provides an attractive alternative to conventional ileocolonoscopy to evaluate luminal disease activity in Crohn’s disease (CD). An earlier study showed that pan-CE is feasible, safe and well tolerated by CD patients. The aim of the present study was to assess the Sensitivity TO measure Change (STOC) in mucosal disease activity using pan-CE in CD. Methods Patients with CD and active disease based on symptoms (i.e. Crohn’s disease activity index (CDAI) >150) and inflammatory biomarkers (i.e. C-reactive protein (CRP) >5 mg/L and/or fecal calprotectin (fCal) levels >250 mg/kg) underwent pan-CE, using the second-generation Pillcam colon capsule, prior to and 8-12 weeks after treatment initiation with infliximab, adalimumab or vedolizumab. Luminal disease activity was assessed using the Crohn’s disease endoscopic index of severity (CDEIS) and the simple endoscopic score for Crohn’s disease (SES-CD), expanded with two segments for the jejunum and pre-terminal ileum. Sensitivity to detect mucosal change was assumed if the standardized effect size was >0.8. Correlations between the evolution in CDAI, CRP and fCal with endoscopic activity scores before and after treatment initiation were calculated. Results Twenty-eight patients underwent pan-CE of whom two withdrew consent and four did not start biologic therapy. Twenty-two patients (78.6%) started biologic treatment and underwent pan-CE twice. Median duration between treatment initiation and pan-CE was 11 weeks (IQR: 9.8-12 weeks). Half of patients (11/22) were female and the median age was 24 years (IQR=22-38 years). The standardized effect size was 1.11 for CDEIS and 1.36 for SES-CD. Median CDEIS scores decreased from 6.8 (IQR=4.6-11.2) to 3 (IQR=0.9-6.0, p=0.01). Median SES-CD scores decreased from 15.5 (IQR=9.8-22.5) to 6 (IQR=2.8-11.3, p=0.001). SES-CD score per segment decreased significantly for colon segments, not for small bowel segments (figure 1). The difference in CDAI, CRP and fCal outcomes before and after treatment did not correlate with the change in CDEIS and SES-CD. Conclusion Pan-CE is useful to assess luminal disease activity in CD patients who embark on biological treatment. Pan-CE is sensitive to monitor mucosal healing outcomes and might therefore replace ileocolonoscopy for this indication in CD patients.


2021 ◽  
Vol 93 (6) ◽  
pp. AB22
Author(s):  
Adriaan Volkers ◽  
Geert R. D'Haens ◽  
Peter Bossuyt ◽  
Jitteke de Jong ◽  
Mark Löwenberg

2019 ◽  
Vol 89 (6) ◽  
pp. AB66-AB67
Author(s):  
Salvatore Oliva ◽  
Salvatore Cucchiara ◽  
Marina Aloi ◽  
Francesca Maccioni ◽  
Cesare Hassan ◽  
...  

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Charlotte M. Höög ◽  
Lars-Åke Bark ◽  
Juan Arkani ◽  
Jacob Gorsetman ◽  
Olle Broström ◽  
...  

Aim. To evaluate capsule endoscopy in terms of incomplete examinations and capsule retentions and to find risk factors for these events.Material and Methods. This retrospective and consecutive study includes data from 2300 capsule enteroscopy examinations, performed at four different hospitals in Stockholm, Sweden from 2003 to 2009.Results. The frequency of incomplete examinations was 20%. Older age, male gender, suspected, and known Crohn's disease were risk factors for an incomplete examination. The PillCam capsule had the highest rate of completed examinations. Capsule retention occurred in 1.3% (). Risk factors for capsule retention were known Crohn's disease and suspected tumor. Complications of capsule retention were acute obstructive symptoms in six patients and one death related to complications after acute surgical capsule retrieval.Conclusion: Capsule endoscopy is considered a safe procedure, although obstructive symptoms and serious complications due to capsule retention can be found in a large series of patients.


Sign in / Sign up

Export Citation Format

Share Document